Ángela M. Valverde and María Monsalve, members of ITN TREATMENT, were invited to participate in the Transcription factor NRF2: New opportunities for pharmaceutical innovations in chronic diseases (11-13 of April, 2018). Ángela M. Valverde was invitated to participate with a presentation entitled “Targeting NRF2 in metabolic diseases” and María Monsalve as chairperson. This event was organized by Antonio Cuadrado, member of CiberNed.

Programme
April 11th
Arrival to Hotel Tryp Chamartin
17:30-18:15. Registration
18:15-18:30. Welcome
Antonio Cuadrado
Ana I. Rojo
Albena Dinkova-Kostova
18.30-20.30. Session I. Chair: Ana I. Rojo.
18:30-19:00. From the irreproducibility crisis towards a way forward for translational biomedicine. Harald Schmidt (abstract).
19:00-19:30. Targeting NRF2 in metabolic diseases. Angela M. Valverde (abstract)
19:30-20:00. Advances and needs for the clinical development of SFX-01. Stephen Franklin (abstract).
20:00-20:30. Potential Clinical Applications of Synthetic Triterpenoids Chemistry and Pharmacology. Michael B. Sporn (abstract).
April 12th.
9:00-11:00. Session II. Chair: Coral Barbas.
9:00-9:30. Targeting NRF2 for chemoprotection. Albena Dinkova-Kostova (abstract).
9:30-10:00. NRF2 in atherosclerosis. Anna-Lissa Levonen (abstract).
10:00-10:30. NRF2: a key stone for the development of drugs of the future. Rafael León (abstract).
10:30-11:00. NRF2 in Neurodegenerative Diseases. Antonio Cuadrado (abstract).
11:00-11-30. Coffee break
11:30-13:30. Session III. Chair: María Monsalve.
11:30-12:00. NRF2 in Liver Injury. John Hayes (abstract).
12:00-12:30. Advances and Needs for the Clinical Development of Bardoxolone Methyl and Derivatives. Sharon Cousin (abstract).
12:30-13:00. Clinical Trials Targeting NRF2 for Cancer Chemoprevention: Opportunities and Challenges. Thomas W. Kensler (abstract)
13:00-13:30. Relevance of NRF2 in Joint Conditions. María J. Alcaraz (abstract).
13:30-14:30. lunch
14:30-16:30. Session III. Chair: Ana Casas
14:30-15:00. Advances and Needs for the Clinical Development of NRF2 Activators in the Lung. William Rumsey (abstract).
15:00-15:30. New KEAP1 Inhibitors and their Impact on Mitochondrial Processing. Goeffrey Wells (abstract).
15:30-16:00. Non-electrophilic Activation of the NRF2 Pathway. Otis Attucks (abstract).
16:00-16:30. Electrophilic Fatty Acid Nitroalkenes: Endogenous Signaling Mediators and New Drug Candidates. Francisco Schopfer (abstract).
16:30 -17:30. Coffee and round table: Innovative Therapies Based on Targeting NRF2. What do we need?
Thomas W. Kensler
John Hayes
Albena Dinkova-Kostova
Harald Schmidt
Antonio Cuadrado
17:30-20:30. Session IV. Bilateral meetings
20:30. Shuttle to restaurant
21:00. Closing dinner (Restaurant Café de Oriente, in front of the Royal Palace)
April 13th
Bilateral meetings and departure